Foundation Medicine today announced that it has expanded its immunohistochemistry (IHC) test offerings to include MET IHC testing.

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the addition of a full suite of ...

test offerings to include MET IHC testing using the VENTANA® MET (SP44) RxDx assay, now available as an add-on to comprehensive genomic profiling (CGP) test orders for patients with non-squamous ...

The global immunohistochemistry (IHC) market is experiencing steady growth, with a compound annual growth rate (CAGR) of ...

Guardant Health, Inc. (NASDAQ: GH), a precision oncology company valued at approximately $5 billion, has introduced a complete suite of immunohistochemistry (IHC) testing for key biomarkers in ...

Immunohistochemistry testing, also known as IHC, is a specialized staining technique used to detect specific proteins called tumor biomarkers within tissue samples. These biomarkers reveal ...

Investigators are using MET immunohistochemistry testing and FDA-approved profiling tools to personalize ... United States that has historically and is currently offering the [MET IHC] assay for ...

The Pathology Department of Ongole Government General Hospital (GGH) and Medical College on Monday has launched advanced ...

IRVING, Texas, May 12, 2025 /PRNewswire/ -- Caris Life Sciences®(Caris), a leading next-generation AI TechBio company and precision medicine pioneer, performs MET Immunohistochemistry (IHC) testing as ...

Caris is addressing these challenges by leveraging the power of MET IHC testing, which evaluates the expression of the MET protein in cancer cells. This protein is known to play a crucial role in ...